SEC Form 4 · accession 0001209191-18-057255
TALPHERA, INC. · TLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence G Hamel
Officer — Chief Development Officer
Period of report
Nov 2, 2018
Accepted (ET)
Nov 5, 2018 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001427925
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2018 | A | 5,000 | $2.225 | A | 34,795 | I | By the Hamel Revocable Living Trust |
| Common StockF1 | Nov 2, 2018 | D | 5,000 | $5.00 | D | 29,795 | I | By the Hamel Revocable Living Trust |
| Common Stock | holding | — | — | — | 24,371 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.225 | Nov 2, 2018 | A | 26,125 | A | Nov 2, 2018 | Nov 2, 2028 | Common Stock | 26,125 | 26,125 | D |
| Stock Option (Right to Buy)F2 | $2.225 | Nov 2, 2018 | D | 5,000 | D | Nov 2, 2018 | Nov 2, 2028 | Common Stock | 5,000 | 21,125 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2On April 7, 2018, the reporting person was granted an option to purchase 52,250 shares of common stock. The option vests in two equal annual installments based on Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019; and the remaining 50% of the award shall vest on the one-year anniversary of the date of such FDA approval, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 26,125 shares.